Home › Leukemia › Vermont › Burlington
Leukemia clinical trials in Burlington, VT
4 studies for Leukemia are looking for participants at sites in and around Burlington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RecruitingPhase 3
- University of Vermont Medical Center, Burlington
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- University of Vermont, Burlington
Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens
RecruitingObservational study
- University of Vermont Medical Center, Burlington
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
RecruitingObservational study
- University of Vermont and State Agricultural College, Burlington
About Leukemia
Leukemia is cancer of the white blood cells. There are two types of Leukemias, acute and chronic. Learn about the differences and treatments available.
More about Leukemia on MedlinePlus
Leukemia trials in other cities
- Houston, TX28 studies
- Boston, MA25 studies
- New York City, NY19 studies
- Los Angeles, CA16 studies
- Chicago, IL16 studies
- Durham, NC13 studies
- Baldwin Park, CA12 studies
- Nashville, TN12 studies
- Columbus, OH12 studies
- Philadelphia, PA12 studies
- Milwaukee, WI11 studies
- Atlanta, GA11 studies
Other studies in Burlington
- Heart Failure8 studies
- Acute Myeloid Leukemia7 studies
- Cancer (all types)6 studies
- COPD5 studies
- Breast Cancer5 studies
- Parkinson's Disease4 studies
- Non-Small Cell Lung Cancer4 studies
- Prostate Cancer4 studies
- Cystic Fibrosis4 studies
- Lung Diseases4 studies
- Cardiovascular Disease4 studies
- Metastatic Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.